Technological projects portfolio

BK virus nephropathy is an opportunistic viral infection connected to the immunosuppressant used during renal transplant operations.
It affects 10% of kidney transplant patients. The infection leads to loss of the kidney in more than 50% of cases.

There is no specific antiviral treatment and the current diagnostic methods are invasive (renal biopsy), implemented too late and also have a high rate of false negatives (up to 30%).

NEPHROVIR is an innovative method for assessing the risk that BK-virus nephropathy will appear after a kidney transplant. It is based on the analysis of several combined biomarkers.

Non-invasive, quick and very specific, the method allows for early screening and stratification of patients at risk of contracting Bk-virus nephropathy, and therefore makes it possible to adapt their immunosuppressant treatment associated with the transplant.

The NEPHROVIR method provides for better assessment of the patient’s response to post-transplant therapeutic care and allows modulation of the immunosuppressant therapy or any other treatment that could curb the reactivation of the Bk-virus, without requiring biopsy of the transplanted kidney.